Clinical Trials
397
Active:16
Completed:51
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:16
Phase 2:86
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (222 trials with phase data)• Click on a phase to view related trials
Phase 2
86 (38.7%)Not Applicable
79 (35.6%)Phase 3
22 (9.9%)Phase 1
16 (7.2%)Phase 4
15 (6.8%)Early Phase 1
4 (1.8%)Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancers
- Interventions
- Drug: Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Target Recruit Count
- 112
- Registration Number
- NCT07095023
Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study
- Conditions
- AF Ablation Patients With Moderate+ FMR and Persistent AF
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Target Recruit Count
- 556
- Registration Number
- NCT07096219
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
Not Applicable
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Target Recruit Count
- 912
- Registration Number
- NCT07092709
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Not Applicable
Not yet recruiting
- Conditions
- HNSCCPD-1Radiotherapy
- Interventions
- Drug: PD-1inhibitorRadiation: radiotherapy
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Target Recruit Count
- 50
- Registration Number
- NCT07090707
- Locations
- 🇨🇳
Sun yat-sen memorial hospital, Guangzhou, Guangdong, China
Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
Not Applicable
Recruiting
- Conditions
- Skin MicrobiomeRadiation DermatitisBreast Cancer
- Interventions
- Drug: Skin Repairing CreamOther: Cetaphil® Moisturizing Cream as Inactive Control
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Target Recruit Count
- 326
- Registration Number
- NCT07066280
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 79
- Next
News
No news found